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Abstract: Based on extensive blood pressure data and results from a scientific model of the analysis of 
the rate processes involved in polymyositis the evidence suggests that the polymyositis in a particular 
patient was initiated by taking the drug amlodipine besylate (norvasc). The method of our analysis 
should serve as a foundation in handling other drug related interactions. 
 
Key words:  Polymyositis, blood pressure, amlodipine besylate (norvasc), steroid therapy 
 
INTRODUCTION 
 
 On revisiting an extensive blood pressure database 
of a specific polymyositis patient prior to the diagnosis 
of the disease, we have been able to identify when the 
body began producing the chemicals that attacked the 
muscles. Furthermore, the evidence suggests that the 
process was triggered when the patient began to take 
amlodipine besylate (norvasc) in an attempt to reduce 
the blood pressure. 
 For this particular patient, considerable detail is 
given by Golding[1] and extends the mathematical 
model developed earlier[2,3] to control and monitor 
polymyositis. Golding and Giles[4] confirm a significant 
reduction in the muscle inflammation observed from 
two muscle biopsies spanning eight years, illustrating 
the success of the model. 
 For almost five years prior to the diagnosis of 
polymyositis, blood pressure data was gathered 
specifically as a matter of general interest. About two 
years prior to the diagnosis the patient commenced 
taking norvasc. Prior to that, the patient took no drugs. 
In this study we present evidence that suggests that it 
was the norvasc that initiated the onset of polymyositis. 
 
The data measurements: First, we shall consider the 
blood pressure data over a period of 1772 days prior to 
the introduction of prednisolone. We shall find it 
convenient to group the data into two sets, set A and set 
B. 
Set A: from –1772 to –795 days.  
 In set A, the blood pressure measurements were not 
taken daily and represent 69 specific readings spread 
out over the period.  
Set B: from –793 to –1 days. 
 In set B, although the blood pressure measurements 
also were not taken daily they were recorded more 
frequently than in set A, especially when the norvasc 
was commenced and varied. In set B we have 147 
specific readings spread out over the period. The mean 
and standard deviations of the blood pressure data over 
the two sets are given in Tables 1 and 2.  
 Next we may compare the results using the 
Student’s t-test p-value[5](Table 3). If the p-value is 
greater than 0.995 then the distributions are 
significantly different. For the comparison between set 
A and set B, the only value that has not been affected is 
the pulse pressure. Hence, over the entire period of 
1772 days, the mean pulse pressure was 50.333 mmHg 
with a standard deviation of 7.0720 mmHg. To 
illustrate the change between sets A and B data, we 
have shown the two heart rate distributions in Fig. 1.  
 Figure 1 highlights that an abrupt change in the 
heart rate took place following day –795. This 
coincides with the day that the patient started taking 
norvasc. From day –795 to day –392 days, 5 mg or 10 
mg norvasc was used. From day –315 until the 
prednisolone was introduced, 0.5 or 0.1 mg trandolapril 
(odrik) was used. During these two periods, norvasc 
and or, odrik was used and varied for short periods of 
time. We shall choose the periods when only norvasc 
was used as set C where the data is given in Table 4. 
We shall choose the periods when only odrik was used 
as set D where the data is given in Table 5. 
 From Table 3, by comparing the distributions of 
sets A and C, we establish that taking norvasc changes 
significantly all the blood pressure parameters from 
prior to taking norvasc.  In the case of replacing the 
norvasc with odrik only, comparing the distributions of 
sets A and D, the diastolic and the heart rate are 
significantly changed. Furthermore, by comparing the 
distributions of set C and set D it follows that the 
evidence is that all the blood pressure parameters have 
been significantly changed by replacing norvasc with 
odrik except for the heart rate. 
 In summary, it is clear that norvasc and odrik 
significantly affect the blood pressure results. It appears 
that the replacement of norvasc with odrik does not 
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change the increase of the heart rate from the initial 
period designated as set A. On the other hand, however, 
the other blood pressure characteristics are 
norvasc/odrik related and also differ from set A. 
 
ANALYSIS OF THE RESULTS 
 
 Prior to day – 795 the patient had not taken any 
drugs. On day –795 the patient commenced taking 5 mg 
per day of norvasc that was suggested in order to reduce 
the blood pressure values. At that point there was a very 
rapid change in the systolic, diastolic and heart rate 
values. In particular, the increase of the heart rate was 
very significant.  
 From Golding[1], we may obtain an estimate, using 
steady state conditions, of the increase of the heart rate 
for our particular patient if it was due to chemicals 
attacking the muscles. We have shown[2] that if the 
prednisolone is taken every second day the heart rate is 
different on day 1 and day 2 some 12 hours and 36 
hours after taking the prednisolone. If we consider the 
25 mg, 50 mg and 75 mg cases with 2 mg of odrik the 
heart rate on day 2 may be approximated as the same in 
all cases, namely, 80.1 per min from 210 data values 
with a standard deviation of 10.89 per min. For day 1 
the mean heart rate values for the 25, 50 and 75 mg 
cases are 82.8 per min, 89.1 per min and 91.6 per min 
respectively. These values may be expressed 
approximately as heart rate=79.0 + 0.18 P where P is 
the predisolone concentration in mg. In the case of no 
prednisolne we have a value of 79.0 per min which is 
close to the common value for day 2. Furthermore, this 
value gives us an estimation of the heart rate value due 
to the chemicals attacking the muscles that give rise to 
the inflammation. From Table 2 we observed a heart 
rate value of 79.0 per min following the intake of 
norvasc. Since day 2 is approximately independent of 
the prednisolone concentration over that range and is 
close to this value it implies that as far as the heart rate 
is concerned it appears to be constant and effectively 
related to the maximum level of the chemicals attacking 
the muscles.  
 Another approach is to examine the effect of a 
much higher prednisolone intake over a few days, 
where the average prednisolone concentration is very 
small and where the removal of the chemicals affecting 
the heart rate on the other hand is high. This is 
illustrated in Fig. 2 when prednisolone was initially 
used at 60 mg per day for six days with 0.1 mg per day 
of odrik. In this case, the observed heart rate decreased 
from about 85 per min to about 70 per min, the lower 
value in Fig. 1. We estimate that the average 
prednisolone concentration over that short period was 
about 0.24 to 0.35 mg, well below the value for the 
natural decay of about 8.57 mg. 
 Prior to the introduction of prednisolone and using 
only 0.1 mg per day of odrik the mean heart rate over a 
220-day period was 85.4 per min.  
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Fig.1: The heart rate 1772 days prior to the 
prednisolone intake. The standard deviations of 
the two distributions between the data in sets A 
and B are shown. Note that the abrupt change in 
the heart rate following day –795 coincide with 
the day that the patient started taking norvasc 
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Fig. 2:  The observed heart rate seven days before and 
six days after the intake of 60 mg of 
prednisolone per day 
 
These results reflect the processes taking place as 
defined in the model. Furthermore, it is clear that the 
chemicals interacting with the muscle yielding muscle 
inflammation increases the heart rate corresponding to 
that observed in Fig. 1. Secondly, the prednisolone 
level used to control the muscle inflammation also 
increases the heart rate. In Fig. 2 the introduction of a 
high concentration of prednisolone indicates a reduction 
in the heart rate within a few days. On day 7 the 
prednisolone intake was reduced to 50 mg per day. The 
heart rate remained low for a few days before 
increasing to about 90 per min indicating that the 
prednisolone concentration was now affecting the heart 
rate.  
 Hence at a very high prednisolone concentration 
we observe two effects on the heart rate, namely, (i) the 
impact of the prednisolone and (ii) the prednisolone 
reducing significantly the chemicals giving rise to the 
inflammation. On the other hand at a moderate 
prednisolone concentration we observe only one effect 
on the heart rate, namely, (i) the impact of the 
prednisolone. 
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Table 1: The summary of the data for set A i.e. for the period –1772 to –795 days 
set A Systolic mmHg Diastolic mmHg Pulse pressure mmHg Heart rate per minute 
data points 69 69 69 54 
mean 142.41 89.406 53.000 71.370 
standard deviation 8.5532 5.9685 6.387 8.4190 
 
Table 2:  The summary of the data for set B i.e. for the period –793 to –1 days 
set B Systolic mmHg Diastolic mmHg Pulse pressure mmHg Heart rate per minute 
data points 147 147 147 147 
mean 132.62 82.993 49.626 79.034 
standard deviation 11.399 6.8502 7.1970 8.4606 
 
Table 3: The Student’s t test p-value comparing several distributions 
 Systolic mmHg Diastolic mmHg Pulse pressure mmHg Heart rate per minute 
A-B 1.000 1.000 0.957 1.000 
A-C 1.000 1.000 1.000 1.000 
A-D 0.992 0.999 0.701 1.000 
B-C 0.992 0.974 0.975 0.751 
B-D 0.998 0.992 0.985 0.914 
C-D 1.000 1.000 1.000 0.964 
 
Table 4: The summary of the blood pressure data over the period when only 5 mg or 10 mg of norvasc was taken each day 
set C Systolic mmHg Diastolic mmHg Pulse pressure mmHg Heart rate per minute 
data points 91 91 91 91 
mean 128.97 81.187 47.780 78.286 
standard deviation 10.674 6.922 6.588 7.799 
 
Table 5: The summary of the blood pressure data over the period when only 0.5 mg or 0.1 mg of odrik was taken each day 
set D Systolic mmHg Diastolic mmHg Pulse pressure mmHg Heart rate per minute 
data points 45 45 45 45 
mean 138.07 85.756 52.311 81.089 
standard deviation 10.001 5.621 7.245 9.591 
 
 The results from Figs. 1 and 2 thus reinforce that 
the increase in the heart rate, following the introduction 
of norvasc, corresponds to the production of chemicals 
that effect the heart rate and may be radically reduced 
by using prednisolone under controlled conditions. 
Moreover, these results give an insight, previously 
unavailable in developing the model, of the likely time 
dependence of the chemicals affecting the muscles 
associated with the prednisolone interactions. (The 
model was primarily developed to handle steady state 
conditions and focussed on the processes associated 
with the chemicals that affected the muscles and not the 
heart rate, although they will be correlated.) 
 In a previous study[4] a method for extracting 
muscle information from serum creatine kinase 
measurements flagged that the particular patient began 
having difficulty in climbing stairs and getting up from 
a chair which became increasingly difficult, with 
occasional collapses. This commenced after day –793 
and reinforces the suggestion that a muscle problem 
began within 2 days after the first intake of norvasc.  
 Furthermore, a serum creatine kinase value of 949 
IU/L was measured in the patient on day –355. (Note 
that norvasc was still being taken.) It was not until after 
day –40, following a muscle biopsy, that the patient 
was diagnosed as having polymyositis with chronic 
muscle inflammation. This was supported by the 
observation, over the period, of muscle wastage, in 
particular within the upper left leg (thigh)[4]. 
 Hence we have shown that the rapid significant 
increase in the heart rate may be explained very simply 
as due to the chemicals arising from polymyositis, 
where the rate of production of the chemicals occurred 
very rapidly on the introduction of norvasc. We may 
show also from the rate steps involving the chemicals 
attacking the muscles, that the release of additional 
creatine kinase by the muscles would rapidly increase 
to over 90% of the maximum value within four days. 
This would reflect what the patient experienced. After a 
year norvasc was replaced by trandolapril (odrik). We 
note that a detailed analysis of the blood pressure data 
show no justification in giving the patient norvasc and 
the diagnosis that the patient had Buerger’s disease 
(thromboangiitis obliterans) that involves both arteries 
and veins, especially those of the lower extremities, has 
never been supported. Next we shall assess the 
information available in an attempt to quantify what has 
occurred. 
 First we shall address the change in the heart rate. 
Most publications report that norvasc has no effect on 
the heart rate[6-10]. In a few cases norvasc has increased 
slightly the heart rate[11] and in one case[12] the increase 
was about 4 beats per min. There appears to be no 
previous publication that shows any increase that even 
comes close to what we have observed and measured. 
 In a recent study[4] we outlined for a particular 
patient the monitoring and management of 
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inflammatory disease and the likely processes taking 
place. A muscle biopsy, following almost two years 
after the norvasc intake was commenced, and over 
which period muscle difficulties were increasing, as 
supported by our heart rate analysis showed that the 
severe muscle inflammation was due to polymyositis. 
The second muscle biopsy, some eight years later, 
showed a major change with no muscle inflammation 
characterised. However, ragged red fibres were 
observed. Ragged red fibres due to mitochondrial 
changes are commonly found in the later stages of 
inclusion body myositis[13]. This observation would 
support the case as discussed in[4] that the muscle 
inflammation appears to be generated by two processes 
as quantified in[4] as process (a) and process (b). If 
process (c) was involved, muscle inflammation would 
have been observed. Furthermore, there is no indication 
that the rates of the chemicals attacking the muscles 
have changed over the years. The reduction in the 
muscle attack, estimated to be about 90%, is due to the 
prednisolone interaction with the chemicals that cause 
the muscle inflammation. 
 Norvasc is a Ca2+ channel blocker used for mild to 
moderate essential hypertension and for the treatment 
of angina pectoris ie. norvasc is a calcium ion influx 
inhibitor (slow channel blocker or calcium ion 
antagonist) that inhibits the transmembrane influx of 
calcium ions into cardiac and smooth muscle without 
changing serum calcium concentrations; the mechanism 
of the antihypertensive action of norvasc is due to a 
direct relaxant effect on vascular smooth muscle 
(MIMS Desk Reference 2004). After oral 
administration of therapeutic doses, norvasc is absorbed 
with peak blood levels between 6-12 hours post dose. 
According to MIMS (MIMS Desk Reference 2004), 
less common side-effects of norvasc are muscle cramps 
and myalgia. Pfizer found that most adverse reactions 
were of mild or moderate severity in controlled clinical 
trials directly comparing norvasc (n=1730), in doses up 
to 10 mg, to placebo (n=1250); muscle cramps occurred 
in less than 1% in placebo controlled trials. 
 
CONCLUSION 
 
 In summary, at and following the introduction of 
norvasc, the heart rate increased significantly. The 
increase corresponds to the observed heart rate 
measurements at steady state when the prednisolone 
concentration is much lower than the value used to 
effectively control the polymyositis. Secondly, the heart 
rate prior to the norvasc intake was obtained by using a 
high prednisolone intake for a few days. All the 
evidence underpins the suggestion that norvasc almost 
instantaneously triggered the rate of production, in our 
specific patient, of the chemicals that characterise the 
muscle attack leading to chronic muscle inflammation. 
Previous work[2] has shown that the rate of production 
of these chemicals has not changed at least since the 
diagnosis of polymyositis. 
 Finally, this work illustrates the dangers of 
administering any drug without an understanding of the 
likely process or processes that may occur and the lack 
of knowledge to control and monitor the processes in a 
scientific way from appropriate detailed data. 
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